Challenges in the practical implementation of blood biomarkers for Alzheimer's disease
- PMID: 39369727
- DOI: 10.1016/j.lanhl.2024.07.013
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease
Abstract
Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal fluid biomarkers to blood biomarkers-eg, to verify amyloid β pathology-requires careful consideration. This Series paper highlights the main challenges in the implementation of blood biomarkers for Alzheimer's disease in different possible contexts of use. Despite the robustness of measuring blood biomarker concentrations, the widespread adoption of blood biomarkers requires rigorous standardisation efforts to address inherent challenges in diverse contexts of use. The challenges include understanding the effect of pre-analytical and analytical conditions, potential confounding factors, and comorbidities that could influence outcomes of blood biomarkers and their use in diverse populations. Additionally, distinct scenarios present their own specific challenges. In memory clinics, the successful integration of blood biomarkers in diagnostic tests will require well-established diagnostic accuracy and comprehensive assessments of the effect of blood biomarkers on the diagnostic confidence and patient management of clinicians. In primary care settings, and even more when implemented in population-based screening programmes for which no experience with any biomarkers for Alzheimer's disease currently exists, the implementation of blood biomarkers will be challenged by the need for education of primary care clinical staff and clear guidelines. However, despite the challenges, blood biomarkers hold great promise for substantially enhancing the diagnostic accuracy and effectively streamlining referral processes, leading to earlier diagnosis and access to treatments. The ongoing efforts that are shaping the integration of blood biomarkers across diverse clinical settings pave the way towards precision medicine in Alzheimer's disease.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests MS has served on the advisory boards for Roche and Novo Nordisk; received speaker honoraria from Bioarctic, Novo Nordisk, and Roche; and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk, and Roche (outside the scope of the submitted work). MS is a co-founder of Centile Bioscience, which develops imaging-based diagnostic support solutions and serves as an Associate Editor of Alzheimer’s Research & Therapy. IMWV declares honoraria from Quanterix. MdC declares contracts or grants from the Ministerio Español de Ciencia e innovación (PROYECTOS I+D+I – 2020 – Retos de investigación), Europe Research 2020 dynamisation actions:payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novo Nordisk and Springer Healthcare; participation as an associate editor at Alzheimer´s Research & Therapy; on the review board of Galen and Hilary Weston Foundation, and the review board of Alzheimer’s Research UK; and travel support from the Alzheimer’s Association. JT declares consulting fees from the Neurotorium Educational Platform. SP declares support from Avid, ki:elements, and Alzheimer's Drug Discovery Foundation; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bioarctic, Biogen, Eisai, Lilly, and Roche. DA declares contracts or grants from the Institute of Health Carlos III and the Department of Health Generalitat de Catalunya; participation in advisory boards of Fujirebio-Europe, Roche Diagnostics, Grifols SA, and Lilly; and speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmaceutica, Zambon, and Esteve Pharmaceuticals. DA declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). CD and JRC declare no competing interests.
Similar articles
-
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.Lancet Neurol. 2022 Aug;21(8):726-734. doi: 10.1016/S1474-4422(22)00168-5. Epub 2022 May 25. Lancet Neurol. 2022. PMID: 35643092 Review.
-
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.J Intern Med. 2021 Sep;290(3):583-601. doi: 10.1111/joim.13332. Epub 2021 Jun 26. J Intern Med. 2021. PMID: 34021943 Free PMC article. Review.
-
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5. Lancet Neurol. 2020. PMID: 32333900
-
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe.J Prev Alzheimers Dis. 2023;10(3):426-442. doi: 10.14283/jpad.2023.43. J Prev Alzheimers Dis. 2023. PMID: 37357283
-
Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics.Clin Chem Lab Med. 2024 Jan 23;62(6):1063-1069. doi: 10.1515/cclm-2023-1434. Print 2024 May 27. Clin Chem Lab Med. 2024. PMID: 38253262 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical